- Medtronic Cryoablation Superior to Drug Therapy for Symptomatic Paroxysmal Atrial Fibrillation
- Medtronic Reports First Quarter Financial Results
- Medtronic Board Appoints Kevin Lofton as a New Director
- Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2021
- Medtronic Evolut TAVR System Receives Updated U.S. Labeling Revising Precaution for Treatment of Low-Risk Patients with Bicuspid Aortic Stenosis
- Medtronic Begins Post-Market, Real-World Study of the InterStim™ Micro System
- Study Published in The New England Journal of Medicine Demonstrates Patients Experience Fewer Disruptions to Dialysis Therapy When Treated with Medtronic Drug-Coated Balloon
- Medtronic to Announce Financial Results for Its First Quarter of Fiscal Year 2021
- Medtronic to Acquire Smart Insulin Pen Company Companion Medical
- Medtronic Announces Comprehensive U.S. Launch of New InterStim™ Micro Neurostimulator
More ▼
Key statistics
As of last trade Medtronic PLC (2M6:STU) traded at 96.06, -3.47% below its 52-week high of 99.51, set on Feb 16, 2021.
52-week range
Markit short selling activity
Open | 96.06 |
---|---|
High | 96.06 |
Low | 96.06 |
Bid | 99.10 |
Offer | 99.33 |
Previous close | 97.42 |
Average volume | 595.60 |
---|---|
Shares outstanding | 1.35bn |
Free float | 1.34bn |
P/E (TTM) | 55.96 |
Market cap | 159.18bn USD |
EPS (TTM) | 2.11 USD |
Annual div (ADY) | 1.89 EUR |
---|---|
Annual div yield (ADY) | 1.97% |
Div ex-date | Dec 21 2020 |
Div pay-date | Jan 15 2021 |
Data delayed at least 15 minutes, as of Mar 05 2021.
More ▼